Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNLIP | P16233 | 17/20 | 0.82 |
| ▸ | STK39 | Q9UEW8 | 3/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.67 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24438027 | 1.00 | PNLIP (0.82) | PNLIPSTK39MEN1HSPD1PIK3CA | |
| SCHEMBL24438299 | 0.93 | PNLIP (0.80) | PNLIPSTK39 | |
| SCHEMBL30692665 | 0.93 | PNLIP (0.80) | PNLIPSTK39 | |
| SCHEMBL23685884 | 0.91 | PNLIP (0.83) | PNLIPSTK39MEN1HSPD1PIK3CA | |
| SCHEMBL23685789 | 0.89 | PNLIP (1.00) | PNLIPSTK39 | |
| SCHEMBL30692660 | 0.87 | P2RX1 (0.82) | PNLIPSTK39P2RX1 | |
| SCHEMBL24438051 | 0.87 | P2RX1 (0.82) | PNLIPSTK39P2RX1 | |
| SCHEMBL29655258 | 0.86 | PNLIP (0.83) | PNLIPSTK39MEN1HSPD1PIK3CA | |
| SCHEMBL24438029 | 0.86 | PNLIP (0.83) | PNLIPSTK39MEN1HSPD1PIK3CA | |
| SCHEMBL31485717 | 0.85 | PNLIP (0.61) | PNLIPSTK39 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406831-A1 | COMPOUNDS AND METHODS OF INHIBITING BACTERIAL CHAPERONIN SYSTEMS | THE TRUSTEES OF INDIANA UNIVERSITY | 2023-12-21 | — | — | US | disclosed |
| EP-4243799-A1 | COMPOUNDS AND METHODS OF INHIBITING BACTERIAL CHAPERONIN SYSTEMS | The Trustees of Indiana University (US) | 2023-09-20 | — | — | EP | disclosed |
| WO-2022103572-A1 | COMPOUNDS AND METHODS OF INHIBITING BACTERIAL CHAPERONIN SYSTEMS | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2022-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406831-A1 | COMPOUNDS AND METHODS OF INHIBITING BACTERIAL CHAPERONIN SYSTEMS | HSP90B1, HSPBP1, HSP90AB1 | PNLIP 841/4885STK39 3354/4885MEN1 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.